GU Cancers Symposium 2014 - Response to androgen signaling-directed therapy after treatment with abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer: Post hoc analysis of study COU-AA-302 - Poster

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Matthew R. Smith, Shannon Matheny, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Johann Sebastian De Bono, Eric Jay Small, Neal D. Shore, Karim Fizazi, Thian San Kheoh, Jinhui Li, Mary Beth Todd, Thomas W. Griffin, Margaret K. Yu, and Charles J. Ryan at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 Smith AA thumb

 

Harvard Medical School and Massachusetts General Hospital, Boston, MA; Janssen Research & Development, LLC, Los Angeles, CA; University of Montréal, Montréal, QC, Canada; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC; Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Janssen Research & Development, LLC, Raritan, NJ; Janssen Global Services, Raritan, NJ